Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas S Downing

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
JAMA Internal Medicine|February 10, 2015
Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?Nicholas S Downing
European Heart Journal. Quality of Care & Clinical Outcomes|September 21, 2017
Ischaemic heart disease in China: the time to address rising mortality ratesNicholas S Downing, Jing Li
JAMA|May 29, 2014
Trial evidence and approval of therapeutic agents--replyNicholas S Downing, Joseph S Ross
Circulation. Cardiovascular Quality and Outcomes|November 13, 2014
Managing the information boundary of an organization: key aspect of translating research into practiceHarlan M Krumholz, Nicholas S Downing
JAMA|January 30, 2014
Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome ServiceNicholas S Downing, Joseph S Ross
JAMA|June 19, 2014
Withdrawal of Personal Genome Service--replyNicholas S Downing, Joseph S Ross
Health Affairs (Project Hope)|April 8, 2015
Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugsJoseph S Ross, Kristina Dzara, Nicholas S Downing
The New England Journal of Medicine|April 6, 2017
Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015Nicholas S Downing, Audrey D Zhang, Joseph S Ross
JAMA Internal Medicine|July 30, 2014
Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional studyJames W Smithy, Nicholas S Downing, Joseph S Ross
Archives of Internal Medicine|June 12, 2013
Generic competition in a flawed system: pill them, bill them-replyNicholas S Downing, Joseph S Ross, Harlan M Krumholz
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
JAMA Internal Medicine|February 10, 2015
Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?Nicholas S Downing
European Heart Journal. Quality of Care & Clinical Outcomes|September 21, 2017
Ischaemic heart disease in China: the time to address rising mortality ratesNicholas S Downing, Jing Li
JAMA|May 29, 2014
Trial evidence and approval of therapeutic agents--replyNicholas S Downing, Joseph S Ross
Circulation. Cardiovascular Quality and Outcomes|November 13, 2014
Managing the information boundary of an organization: key aspect of translating research into practiceHarlan M Krumholz, Nicholas S Downing
JAMA|January 30, 2014
Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome ServiceNicholas S Downing, Joseph S Ross
JAMA|June 19, 2014
Withdrawal of Personal Genome Service--replyNicholas S Downing, Joseph S Ross
Health Affairs (Project Hope)|April 8, 2015
Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugsJoseph S Ross, Kristina Dzara, Nicholas S Downing
The New England Journal of Medicine|April 6, 2017
Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015Nicholas S Downing, Audrey D Zhang, Joseph S Ross
JAMA Internal Medicine|July 30, 2014
Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional studyJames W Smithy, Nicholas S Downing, Joseph S Ross
Archives of Internal Medicine|June 12, 2013
Generic competition in a flawed system: pill them, bill them-replyNicholas S Downing, Joseph S Ross, Harlan M Krumholz
Pageof 5